Toby Talbot

First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study

Siow Ming Lee, Christian Schulz, Kumar Prabhash et al. · The Lancet · 2023 · 158 citations

Medicine, Oncology, Pharmacology +14

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Martin Schüler, James Chih‐Hsin Yang, K. Park et al. · Annals of Oncology · 2015 · 132 citations · Full text

Medicine, Oncology, Pharmacology +13

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin et al. · Annals of Oncology · 2023 · 93 citations · Full text

Medicine, Oncology, Pharmacology +13

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

Pippa Corrie, Pippa Corrie, Andrea Marshall et al. · Annals of Oncology · 2018 · 67 citations · Full text

Medicine, Clinical Sciences, Oncology +15

Ipilimumab in the real world

Saif Ahmad, Wendi Qian, Sarah Ellis et al. · Melanoma Research · 2015 · 52 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15